Amphastar Pharmaceuticals Inc

Section 1: Company Overview and Fundamentals

1.1 Company Overview:

Amphastar Pharmaceuticals, Inc. (NASDAQ: AMPH) is a biopharmaceutical company that focuses primarily on developing, manufacturing, marketing, and selling technically challenging generic and injectable, inhalation, and intranasal products. Additionally, it sells insulin API products. Most of its finished products are used in hospital or urgent care clinical settings and are primarily contracted and distributed through group purchasing organizations and drug wholesalers.

Kalkine’s Diversified Opportunities Report covers the Company Overview, Key positives & negatives, Investment summary, Key investment metrics, Top 10 shareholding, Business updates and insights into company recent financial results, Key Risks & Outlook, Price performance and technical summary, Target Price, and Recommendation on the stock.

Stock Performance:

• The stock has corrected by 14% in the last three months, furthermore corrected by 31.79% in past nine months.
• The stock is in its lower band of its 52-week range of USD 67.66 and 52-week low price of USD 35.93. Post the announcement of FY23 results the stock has corrected by 22.97% with the current price at a current important support of USD 40-USD 42.
• The price is currently trading below both its long-term (200-day) SMA and its short-term (50-day) SMA , with the current RSI of 50.85.

1.2 The Key Positives, Negatives, and Investment summary

1.3 Top 10 shareholders:

The top 10 shareholders together form ~56.27% of the total shareholding, signifying diverse shareholding. Applied Physics & Chemistry Laboratories, Inc., and BlackRock Institutional Trust Company, N.A. are the biggest shareholders, holding the maximum stake in the company at ~13.97% and ~11.42%, respectively.

1.4 Key Metrics:

In fiscal year 2023, Amphastar (AMPH) outperformed industry medians across various financial metrics, reflecting its strong operational efficiency and profitability. The company demonstrated robust margins compared to industry averages, with EBITDA margin at 36.9% versus the industry median of 22.2%, operating margin at 30.1% compared to 7.5% for the industry, pretax margin at 26.6% versus the industry median of -0.2%, and net margin at 21.7% compared to the industry median of -0.1%. Additionally, AMPH exhibited superior return on equity (ROE) of 23.6%, significantly surpassing the industry median of -5.4%, highlighting its effective utilization of shareholder equity to generate profits and shareholder value. These metrics suggest that AMPH has managed its operations efficiently and achieved strong profitability compared to industry peers, indicating a robust financial position and potential for sustained growth and value creation.

Section 2: Business Updates and Corporate Business Highlights

2.1 Recent Updates:

The below picture gives an overview of the recent updates:

2.2 Insights of FY23:

Section 3: Key Risks & Outlook

Section 4: Stock Recommendation Summary:

4.1 Price Performance and Technical Summary:

Stock Performance:

• The stock has corrected by 14% in the last three months, furthermore corrected by 31.79% in past nine months.
• The stock is in its lower band of its 52-week range of USD 67.66 and 52-week low price of USD 35.93. Post the announcement of FY23 results the stock has corrected by 22.97% with the current price at a current important support of USD 40-USD 42.
• The price is currently trading below both its long-term (200-day) SMA and its short-term (50-day) SMA , with the current RSI of 50.85.

4.2 Fundamental Valuation

Valuation Methodology: EV/Sales Multiple Based Relative Valuation

Markets are trading in a highly volatile zone currently due to certain macroeconomic issues and geopolitical tensions prevailing. Therefore, it is prudent to follow a cautious approach while investing.

Note 1: Past performance is not a reliable indicator of future performance.

Note 2: The reference date for all price data, currency, technical indicators, support, and resistance levels is May 01, 2024. The reference data in this report has been partly sourced from REFINITIV.

Note 3: Investment decisions should be made depending on an individual's appetite for upside potential, risks, holding duration, and any previous holdings. An 'Exit' from the stock can be considered if the Target Price mentioned as per the Valuation and or the technical levels provided has been achieved and is subject to the factors discussed above.

Note 4: The report publishing date is as per the Pacific Time Zone.

Technical Indicators Defined: -

Support: A level at which the stock prices tend to find support if they are falling, and a downtrend may take a pause backed by demand or buying interest. Support 1 refers to the nearby support level for the stock and if the price breaches the level, then Support 2 may act as the crucial support level for the stock.

 Resistance: A level at which the stock prices tend to find resistance when they are rising, and an uptrend may take a pause due to profit booking or selling interest. Resistance 1 refers to the nearby resistance level for the stock and if the price surpasses the level, then Resistance 2 may act as the crucial resistance level for the stock.

 Stop-loss: It is a level to protect against further losses in case of unfavorable movement in the stock prices.

Disclaimer

Kalkine New Zealand Limited is a Financial Advice Provider (“FAP”) and is authorised by a Class 1 Financial Advice Provider Licence issued by Financial Markets Authority (“FMA”) to provide financial advice. Kalkine provides only general financial advice through its research reports following a person becoming a member. The reports contain buy/sell/hold and other recommendations in relation to equity financial products. The recommendations and opinions [on this website] / [in this report] do not take into account any of your investment objectives, financial situation or needs. Before you make a decision about whether to acquire a financial product, you should obtain the Product Disclosure Statement from the product issuer. You should consider the appropriateness of advice taking into account your own objectives, financial situation and needs and seek independent financial advice before making any financial decisions. If you act on the advice in the research reports, you may have to pay fees, expenses or other amounts (but not to Kalkine).  Further information about the complaints and dispute resolution process, as well as information about Kalkine’s duties are available on Kalkine’s website.  Please read our Financial Advice Provider (FAP) disclosure statement and Complaints Handling Guide, which are available on the website.